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Metastatic Disease to 
the Pancreas and Spleen 
Shayna L. Showalter, Eric Hager, and Charles J. Yeo 
 
Isolated metastases to the pancreas and spleen are a rare occurrence. When they are diagnosed, 
pancreatic metastases are most often from renal cell carcinoma, lung cancer, and breast cancer. 
The most common source of splenic metastases is gynecological in origin; the overwhelming 
majority is ovarian. If extensive staging studies reveal these metastases to be isolated, then 
curative resection may be warranted. This review will demonstrate that long-term survival may 
be achieved in patients with isolated metastases and a prolonged disease-free interval. 
Semin Oncol 35:160-171 © 2008 Elsevier Inc. All rights reserved. 
 
Autopsy data demonstrate that metastases to the pancreas and spleen are common. However, in a 
large majority of cases, these lesions represent diffuse spread of a primary cancer to these and 
other sites. Isolated metastases to these organs are a rare clinical event. Herein, we review the 
literature on the most common primary tumors that metastasize to the pancreas and spleen. We 
will discuss the nature of each primary cancer, the general course of disease that leads to distant 
spread, and the treatment options for metastases to the pancreas and spleen, with a focus on 
isolated lesions. 
 
METASTATIC DISEASE TO THE PANCREAS 
The pancreas is a site of metastatic spread from a multitude of different primary neoplasms. One 
example is illustrated in Figure 1. Autopsy data show that 3% to 12% of all patients with diffuse 
metastatic disease have pancreatic involvement.1-5 In a review of 4,955autopsies, Adsay et al 
found that 81 patients had metastatic disease with spread to the pancreas. This study 
demonstrated that the most common primary malignancies that metastasize to the pancreas 
include lung, stomach, colon, and esophageal cancers and lymphoma (Table 1).6 
 A review of the literature, involving the surgical pathology of 355 solitary metastases to 
the pancreas, demonstrated that the five most common cancers with isolated metastases to the 
pancreas include renal, lung, breast, colon, and melanoma (Table 2).7,8 These dataare supported 
by a single-institution report of 1,050 fine-needle aspiration (FNA) biopsies of pancreatic 
lesions.9 Volmar et al identified 20 metastases: nine from renal cell carcinoma, three from lung 
carcinoma, two from breast carcinoma, one from prostate carcinoma, and one from a 
gastrointestinal stromal tumor.9  
The definitive diagnosis of secondary pancreatic lesions is often difficult because the 
presenting clinical picture may be similar to that of primary pancreatic cancer or the patient may 
be entirely asymptomatic. Patients with metastases to the pancreas usually are identified in one 
of three ways: the pancreatic lesion is discovered during initial metastatic work-up, the lesion is 
identified during routine follow-up after resection of the primary cancer, or the patient presents 
with symptoms secondary to the pancreatic lesion. In a review of patients with pancreatic 
metastases, Minni et al found that 22% of the patients with secondary pancreatic neoplasms 
presented with synchronous lesions at the time of their primary diagnosis.7 Hiotis et al reported 
that 69% of the patients with isolated metastatic disease to the pancreas were asymptomatic at 
the time of  presentation.10 Radiologic findings that arouse suspicion for metastatic disease to 
the pancreas rather than a primary neoplasm include hypervascularity of lesions, absence of 
lymphadenopathy, and multicentricity.11,12  As seen with primary pancreatic neoplasia, patients 
with secondary malignancies can present with painless jaundice, early satiety, epigastric pain, 
and gastrointestinal bleeding. 
Resectional options depend on the type of primary tumor, location of the metastasis, and 
the extent of disease. When a patient presents with widely metastatic disease, most investigators 
agree that there is no role for pancreas-focused metastectomy. Surgical treatment options depend 
on the physical location of the metastasis and include pancreaticoduodenectomy, distal  
pancreatectomy, total pancreatectomy, central pancreatectomy, and, rarely, enucleation. A 
discussion of specific tumors metastatic to the pancreas follows. 
 
Renal Cell Carcinoma 
Renal cell cancers (RCCs) are relatively uncommon  malignancies. Approximately 51,000 new 
cases were diagnosed in 2007, accounting for only 3% of all newly diagnosed cancers.13 Only 
10% of patients with RCC present with the classic triad of gross hematuria, flank pain, and a 
palpable mass. However, presenting symptoms are notoriously variable with this disease, and 
can include anemia, microscopic hematuria, and the sudden onset of a varicocele.14 Many 
lesions are now discovered as asymptomatic incidental findings on imaging. The most important 
prognostic factors relate to the gross size and extent of the primary lesion, and the presence of 
metastatic disease. Patient survival varies with disease stage. The estimated 5-year survival 
approximates over 80% for organ-confined localized disease, and 0% to 20% for metastatic 
disease.15 
Ultrasound in conjunction with computed tomography (CT) scan is the modality of 
choice for identifying renal masses.16 With the increasing use of abdominal CT and ultrasound, 
there has been an increase in the detection of incidental RCCs.17 Current medical treatment of 
disseminated RCC is improving but remains disappointing, and, therefore, the diagnosis of early 
stage RCC is the key to substantially improving survival.  
Surgery is the only treatment modality for RCC that has the possibility of cure. For 
patients found to have a single suspicious renal mass, the treatment of choice is nephrectomy, 
with postoperative surveillance. Traditionally, radical nephrectomy, including Gerota’s fascia 
and the associated adrenal gland, is performed to ensure appropriate resection. Recently, there 
has been a move away from radical surgery, and more RCCs are being treated with adrenal-
sparing, laparoscopic or partial nephrectomy. Adjuvant therapy following surgery is still 
unproven, and has included interferon-alpha, radiation therapy, and autologous tumor 
vaccines.18,19  
Approximately 25% of newly diagnosed patients will have either locally advanced or 
widely metastatic cancer which is not amenable to surgery.20,21 The most common sites of RCC 
metastases are the lung, lymph nodes, bone, liver, brain, ipsilateral adrenal, contralateral kidney, 
and pancreas.22   
Although medical options are disappointing with widely metastatic RCC, they are often explored 
when surgical intervention is not indicated.20 Current medical treatment for metastatic RCC 
includes chemotherapy, targeted therapy, and immunotherapy. Response rates of metastatic 
disease to chemotherapeutics and surgical intervention are generally poor. In 1993, a trial 
of approximately 3,600 patients placed on single- or double-drug chemotherapy regimens 
demonstrated an average response rate of only 5.5%.23 When compared to monotherapy, 
double-drug chemotherapy has been shown to produce a slightly higher response rate, but 
many patients are not able to tolerate the increased side effect profile.24 Recently there has been 
enthusiasm for immunotherapy in the treatment of metastatic RCC. Because RCC evokes an 
immune response, it was theorized that cytokines could be useful in treatment regimens, 
a theory based on the innate properties of cytokines to stimulate the immune system. Initially, the 
targeted use of cytokines showed promising results. However, their use has not been associated 
with a significant survival advantage in the majority of studies with advanced RCC.25-27 Newer 
targeted agents now widely used to treat metastatic RCC include sorafenib and sunitinib. 
A review of surgical pathology reports reveals RCC to be the most common cancer 
associated with solitary metastasis to the pancreas (Table 2).7,9 In general, evidence 
of pancreatic metastases in cancer patients represents diffuse systemic disease. Of note, RCC is 
more commonly associated with isolated metastatic disease to the pancreas, and therefore these 
lesions are potentially more amenable to surgery.28 Autopsy data from patients who succumbed 
to RCC identified metastases to the pancreas in approximately 1.75% of patients.29 After 
resection of the primary tumor, recurrence is often delayed a number of years. In a review of 
patients with metastatic RCC, Sellner et al reported only 12% of pancreatic metastasis to be 
synchronous with the primary renal tumor.30 In fact, most patients who presented with 
pancreatic metastasis from RCC did so an average of 9.2 years after initial resection (Table 
3).5,31-35 Thus, patients must be followed closely for evidence of disease spread, since those 
with recurrence tend to be asymptomatic and are often diagnosed only during follow-up imaging. 
It is interesting to note that a literature review by Wente et al found there to be a slight 
predilection for pancreatic metastasis from a left kidney primary (58%), although this left-sided 
predilection is not supported in all series.11 
Metastasectomy at the time of nephrectomy provides a survival benefit over nephrectomy 
alone for patients found to have synchronous, solitary metastatic lesions.31,35 Surgical options 
for pancreatic metastasis must be carefully planned and individualized to each patient. Resection 
must aim to achieve clear margins, while leaving as much healthy pancreatic parenchyma 
as possible. Total pancreatectomy is therefore the last resort for resection, and carries a higher 
postoperative morbidity than segmental resection alone.28 A review of patients who underwent 
pancreatic resection yielded a 5-year survival post-pancreatectomy between 53% and 75% 
(Table 3). Patients with widely metastatic disease or who choose not to have surgical 
intervention can expect a 5-year survival of only 5% to 30%.35,36 It is likely that surgical 
intervention for solitary pancreatic metastasis from RCC provides a survival benefit, although 
such benefit may be due to both the extent of disease and the surgical resection.5,20,33,37,38  
 
Lung Cancer 
Lung cancer is the most common cause of cancerrelated death in the United States.13 Lung 
cancer is typically classified as either small cell lung cancer (SCLC) or non-small cell lung 
cancer (NSCLC: squamous cell carcinoma, adenocarcinoma, and large cell  carcinoma), based 
on pathologic parameters.  
SCLC, which represents 14% of all new lung cancers, is an aggressive disease 
characterized by rapid doubling time and the early development of widespread metastases. 
Ninety-five percent of all SCLCs can be linked to tobacco use. Although considered to be 
highly responsive to chemotherapy and radiotherapy, SCLC usually relapses quickly, and more 
than 95% of patients will eventually die of the disease.39 Because patients typically present with 
disseminated disease, treatment is usually focused on systemic therapy, not surgery. In the 
occasional case where SCLC presents as a solitary pulmonary nodule (T1N0M0 or T2N0M0), 
surgical resection may be considered, in addition to systemic chemotherapy.40 
NSCLCs, which represent 85% of lung cancers, are differentiated based on 
histopathology. Surgical resection continues to be the primary treatment for NSCLC 
patients who present with localized, resectable disease. Adjuvant chemotherapy is also 
recommended for patients with completely resected early-stage NSCLC.41,42 Because 
metastatic spread is typically considered a contraindication to surgery with a curative intent, 
aggressive efforts must be made to detect nodal disease, mediastinal spread, and distant 
metastases prior to surgical resection. 
The most common sites of metastatic spread from primary lung cancer include the brain, 
bone, liver, adrenal glands, and skin. Within the abdomen, metastases from lung cancer are most 
commonly found in the liver, adrenal glands, abdominal lymph nodes, and kidneys.43 Pancreatic 
metastases from lung primaries are found infrequently in patients with widely disseminated 
disease; these lesions are discovered most often during autopsy (see Table 1). In a retrospective 
study of 22 patients with pancreatic metastases, Moussa et al found four patients with primary 
lung cancer.8 The median time to diagnosis of the metastatic lesion in the pancreas was 4.5 
months after discovery of the primary lung lesion. Two of the patients were diagnosed by 
surveillance, and the other two were diagnosed after the development of jaundice. At the time 
that the pancreatic lesions were identified, all of the patients had diffuse metastatic disease, local 
recurrence, or local spread. Congruent with the treatment of all metastatic lung cancers, these 
patients were not treated with surgical metastectomy. Two of the patients were treated with 
palliative billary stents for tumor-associated obstructive jaundice. Isolated pancreatic metastases 
from lung cancer are extremely rare. Combined data from institutional reviews of patients with 
apparently isolated metastases to the pancreas revealed that 30% of the patients had primary lung 
cancer.5,10 The pancreatic lesions were found incidentally, or secondary to jaundice or 
gastrointestinal bleeding. In a single-institution review, Hiotis et al found that three of the 16 
patients who underwent pancreatic resection for isolated metastases to the pancreas had a 
primary lung cancer.10 These patients underwent either distal pancreatectomy or 
pancreaticoduodenectomy. Although this study demonstrated a slight increase in the disease-free 
interval in the patients with primary renal cell carcinoma, there was not a significant long-term 
survival advantage after pancreatic metastasectomy for patients with a primary lung cancer. At 
the end of the study, two of the three patients with lung cancer were dead of disease, and the 
third was alive with disease. Z’graggen et al reported that four of their 10 patients with isolated 
pancreatic metastases had primary lung cancer. There was a median interval of 70 months 
between treatment of the primary lung cancer and identification of the metastases. Surgery for 
these patients served to provide a definitive diagnosis of the lesion, as well as to palliate 
obstructive symptoms. The tumors were not resected with curative intent.5 These data suggest 
that unlike RCC, patients with lung cancer with apparent solitary metastatic spread to the 
pancreas have a poor prognosis and do not routinely benefit from metastectomy. 
 
Breast Cancer 
Breast cancer, one of the most prevalent cancers found in women today, ranks third in overall 
cause of cancer death in the United States. It is estimated that in 2007, more than 178,000 
women in the United States were diagnosed with breast cancer, and another 40,000 died of the 
disease.13 Ten percent of women with breast cancer will have metastatic disease at the time of 
presentation.  
Breast cancer most commonly spreads to the liver, brain, adrenals, lung, ovary, and bone. 
The evaluation of a patient with suspected metastatic disease should include extensive full body 
imaging and a bone scan. The median survival for patients with widely metastatic 
disease is approximately 18 to 24 months. The 5-year survival has been reported to be as low as 
5% to 10%.44-47 Although stage IV breast cancer is generally not a surgical illness, many 
studies have shown a survival benefit to metastasectomy of solitary lesions, especially 
those found in the liver and lung.48-52 
Metastasis to the pancreas from breast cancer usually occurs in the setting of diffusely 
metastatic multiorgan disease. Isolated pancreatic involvement in breast cancer is uncommon, 
although there are a few published series. In a study of 333 cases of isolated metastasis to the 
pancreas, Minni et al reported that only 25 (8%) were from a breast primary.7 Of note, an 
analysis of autopsy data from 707 patients who died of metastatic breast cancer demonstrated 
that 13% had pancreatic involvement.53 This indicates that although isolated metastases to the 
pancreas are uncommon, the pancreas may be involved in widely metastatic breast cancer. Breast 
cancer patients with pancreatic involvement present with symptoms typical of pancreatic lesions 
including jaundice, weight loss, and abdominal pain.54-56 Jaundice in the presence of a history 
of breast cancer is usually an ominous sign, indicating diffuse hepatic involvement and an 
average life expectancy of only 1 month.57-59 However, imaging is very important in these 
patients, as extrahepatic bile duct obstruction by a metastatic lesion to the periampullary region, 
while rare, can mimic diffuse hepatic metastases, and can be palliated with a biliary 
endoprosthesis. 
The average latency period between the treatment of a primary breast cancer and the 
identification of a pancreatic recurrence is approximately 74 months (Table 4).52,54-60 It has 
been hypothesized that such a long latency may indicate a slow-growing tumor, more amenable 
to either curative or palliative surgery.5 While controversial, surgical resection of pancreatic 
metastasis from breast primaries, in conjunction with chemotherapy, hormonal therapy (for 
receptor positive tumors), and radiation therapy may improve survival in carefully selected 
individuals.5,54-60 
 
Colon Cancer 
Colon cancer is highly prevalent in Western societies. The mortality from colon cancer accounts 
for 10% of all cancer deaths, ranking second only to lung cancer. 13 The incidence of colon 
cancer increases with age, yielding an average lifetime risk of 5%.61 Over the past 20 years there 
has been an improvement in the 5-year survival rate. This is generally attributed to earlier 
detection and improved chemotherapeutics.62 As the risk factors for colon cancer have become 
better defined, so have the guidelines for screening and surveillance, leading to a reduction in 
advanced disease at initial presentation. Of all patients diagnosed with colon cancer, 
approximately 5.5% to 12% will have locally advanced disease, while another 30% to 40% will 
have metastatic disease at initial diagnosis.63 
Pancreatic metastasis from colon cancer most often occurs secondary to local invasion 
from primaries involving either the transverse or right colon. Extensive, en bloc resection of 
locally advanced colon cancer has been studied and found to improve prognosis, and in 
some cases to provide a definitive cure.64-66 A recent review of the literature found the 5-year 
survival of patients who had an incomplete, margin-positive resection to vary between 0% and 
23%, while patients undergoing en bloc resection faired significantly better, with a survival of 
16% to 45% at 5 years.67-69 For patients with locally advanced but node-negative disease, 5-
year survival rates can approach 76% for en bloc resection.70 There have been numerous case 
reports of patients undergoing colectomy plus pancreaticoduodenectomy for pancreas-invading 
colon cancer. In 1994, Curley et al reported 12 patients who underwent extensive en bloc 
resection (colon and pancreas), and found the median survival for all 12 patients to be 32 
months.66 Of note, three of these patients had lymph node–positive disease and died early. 
Berrospi et al reported three patients who underwent en bloc resection (colon and pancreas), and 
were alive at 10, 30, and 113 months post-resection.65 
 
Malignant Melanoma 
Melanoma, the most fatal of all skin cancers, is a leading cause of cancer-related death in the 
United States.13 The incidence of melanoma is rapidly increasing. Melanoma microstaging 
depends on the thickness of the lesion (Breslow classification), or the level of invasion (Clark 
classification).71,72  
The most common sites of distant disease spread from melanoma are lung, liver, brain, 
bone, and the gastrointestinal tract. Visceral metastases occur in 20% of patients as the first site 
of disease spread. Stage IV melanoma is generally incurable and surgical intervention is reserved 
for palliation. In rare cases, there is a survival advantage for the surgical resection of isolated 
distant metastases. This has been shown after complete resection of solitary metastases to the 
lung, hollow viscus organs of the gastrointestinal tract, and the adrenal glands.73 
As previously mentioned, malignant melanoma is commonly associated with metastatic 
disease to the hollow organs of the gastrointestinal tract. Rarely, metastatic lesions are found in 
the pancreas. In a large review of patients with intra-abdominal metastatic melanoma from the 
M.D. Anderson Cancer Center, 16% of the patients had metastatic disease in the pancreas  
however, all of these were accompanied by other intra-abdominal metastases).74 In a review of a 
number of patients with metastatic lesions to the pancreas, melanoma accounted for 2.5% to 15% 
of all cases.4,6,8-10,64,75 
There are only limited data specific to the resection of malignant melanoma to the 
pancreas. In a retrospective review by Wood et al of 60 patients with melanoma 
metastatic to solid intra-abdominal organs, 44 patients underwent complete resection of disease 
in single or multiple organ sites.73 Eight of these patients had secondary lesions in the pancreas. 
Six of the eight underwent complete resection, with a 5-year survival rate of 50%. Two of the 
eight had palliative surgery, with a 5-year survival rate of 0%. Overall, patients undergoing 
complete resection had a significant survival advantage when compared to both non-operative 
patients and patients who underwent partial resection only. This review is the first to demonstrate 
improved survival by the complete resection of multiple organ site metastases from melanoma. 
These results are supported by the M.D. Anderson data, which report increased symptom-free 
and overall survival in highly selected patients able to undergo complete resection of abdominal 
metastases from melanoma.74 
 
METASTATIC DISEASE TO THE SPLEEN 
The spleen is a relatively frequent site of metastasis in disseminated cancer.76 Berge et al found 
the spleen to be the tenth most common site of metastasis, with an incidence of neoplastic 
involvement in 7.1% of autopsy cases of cancer patients.77 Although splenic involvement 
is seen fairly often, isolated metastases to the spleen are exceedingly rare. In 2001, Agha-
Mohammadi et al reported a series of 54 patients, and found the most common primary 
neoplasms to be gynecologic (61%), colorectal (15%), lung (9%), and stomach 
(4%) (Table 5).78 Several hypotheses have been proposed to explain the low incidence of 
isolated metastatic spread to the spleen. It is believed that the spleen possesses an innately hostile 
environment for malignant invasion and residence. The reticuloendothelial system may help to 
inhibit the initial phase of tumor cell seeding.79 If a malignant nidus is established, the 
contraction of the spleen may expunge the cells.80 Lack of afferent lymphatics also may provide 
some protectionto the spleen81 and may explain the typical lack of splenic hilar lymph node 
involvement seen in isolated metastatic lesions.82 A typical splenic metastasis is shown in 
Figure 2. 
Patients presenting with splenic metastases do so with a widely variable clinical picture. 
Agha-Mohammadi et al found that only 21% of patients presented with symptoms of pain, 
splenomegaly, or weight loss.78 In contrast, there have been dramatic reports of spontaneous 
splenic rupture from tumor burden, with a high morbidity rate.83,84 In most patients, splenic 
involvementis detected through routine follow-up imaging. The challenge for the clinician is to 
discern the relatively rare finding of splenic metastasis from the more common primary splenic 
pathology, such as abscess, hemangioma, or infarct.85 Imaging, tumor markers, and FNA all are 
used to diagnose splenic lesions,with acceptable risks.86 When an isolated metastasis is 
confirmed, most investigators agree that a splenectomy should be performed to prevent further 
metastatic seeding and to avoid possible splenic rupture.78,87 
Splenectomy has been performed both laparoscopically and via laparotomy. Most authors 
support using an open approach when operating for malignant conditions. The laparoscopic 
method is limited in these cases because it is frequently necessary to remove metastases 
in other locations and because the spleen is often large. However, for truly isolated metastases to 
the spleen, laparoscopic splenectomy represents a reasonable approach. 
 
Gynecologic Cancers 
The majority of reported cases of isolated splenic metastases are represented by gynecologic 
cancers. In an extensive review of all cases of solitary splenic metastasis, Agha-Mohammadi and 
Calne found 61% to be associated with gynecologic primaries, with the majority being ovarian 
cancer. As with other cancers, splenic involvement from ovarian or endometrial cancers typically 
signifies late disseminated disease. Isolated lesions are rare, with only 33 reported cases.78 
Ovarian cancer patients are closely followed with CT scanning and measurement of the 
tumor marker CA-125. Both of these modalities are useful in the diagnosis of recurrence and 
splenic metastases. Case reports of splenectomy during both primary cytoreductivesurgery and 
secondary debulking are increasingly frequent in the literature.88 It is essential to thoroughly 
examine the abdomen and pelvis for peritoneal carcinomatosis, and to perform multiple biopsies 
to exclude microscopic peritoneal dissemination. Splenectomy for isolated lesions is viewed as a 
relatively safe procedure  that can lead to a prolonged disease-free interval, prior to the 
possibility of disseminated recurrence of ovarian cancer.89 
 
Lung Cancer 
Lung cancer is one of the most common non-gynecologic cancers that metastasize to the spleen. 
Overall, the total proportion of lung cancers that metastasize tothe spleen is low. Satoh et al 
performed a retrospective analysis of 997 patients with lung cancer.90 Only 1.2% of these 
patients were identified to have synchronousor metachronous splenic metastases. These lesions 
were diagnosed via CT scan. This study found that SCLC is the most likely to metastasize to the 
spleen, and that squamous cell carcinoma is the least likely to doso. All 12 patients in this study 
were found to have disseminated disease elsewhere at the time of the diagnosis of splenic 
involvement. 
In a retrospective analysis of 92 patients with secondary nonlymphoid splenic tumors 
recorded over a25-year period, the lung was the primary tumor site in 21%. Four of these 92 
patients had apparent isolated splenic metastases; one of the four represented a primary 
lung adenocarcinoma.91 In a meta-analysis of all cases of solitary metastases to the spleen, 
primary lung cancer accounted for 11%. Splenic metastases originated from bronchioalveolar 
carcinoma, adenocarcinoma, SCLC, and pulmonary carcinoid primary tumors. 78 
Table 6 reviews the small number of reported cases of isolated splenic metastases from a 
primary lung cancer.91-100 These reports underscore that all types of lung cancer have been 
found in the spleen, including a carcinoid tumor. The indication for splenectomy generally 
has been to avoid potential complications such as painful splenomegaly, splenic vein thrombosis, 
and rupture. As with any metastasectomy from a lung primary, there is no evidence that 
splenectomy increases survival. 
 
Colon Cancer 
Isolated splenic metastases from colon cancer are extremely rare. Most patients with metastasis 
to the spleen from colon cancer have widely metastatic disease.An autopsy review showed that 
of 1,019 patients with colon cancer, 21 had splenic metastasis but all were associated with 
diffuse disease.77 In 2001, Okuyama et al performed a world literature search and reported only 
29 cases of isolated splenic metastases from colon cancer primaries.101 The average patient 
presented with splenic metastasis 29 months after the initial colon cancer diagnosis. Most of the 
patients presented with increased CEA found by routine blood work. Of the 29 patients reported, 
28 were treated with a splenectomy and had an estimated 1-year survivalof 86.6% (with a 
median survival of 66 months).  There is currently no long-term follow-up in these patients 
and, thus, the survival benefit is not known.  There are, however, documented cases of splenic 
rupture if surgical intervention is not pursued.102 Thus, even without a documented survival 
advantage, splenectomy should be entertained. 
Malignant Melanoma 
Melanoma has been found to metastasize to the spleen, usually in cases of disseminated disease. 
In the review by Aga-Mohammadi et al, melanoma accounted for only one of the reported cases 
of solitary splenic metastases.77 In a review of 25 patients with abdominal metastases, Gutman 
et al found that the spleen was involved in 15% of cases.74  
Because patients with visceral metastases have a poor prognosis, and solitary metastases 
to the spleen are uncommon, surgery with curative intent is rarely undertaken in these patients. 
The rationale for splenectomy is similar to the previous discussion of complete resection of 
metastases to the pancreas. There are reports that complete resection does increase overall and 
disease-free survival rates.73,74 In the review by Wood et al of 60 patients with intra-abdominal 
solid organ metastases from melanoma, 11 were found to have splenic involvement. All of these 
patients underwent splenectomy with curative intent. Five-year survival data are unfortunately 
not available for this group of patients.73 In a single-institution review of 113 patients found to 
have splenic metastases secondary to melanoma, 15 patients underwent splenectomy.103 Seven 
of the 15 were thought to have a solitary lesion. Median survival after splenectomy was 11 
months for all 15 patients; however, the subgroup of 7 patients with isolated metastases had a 
median survival of 23 months. Median survival of the non-surgical group was only 4 months. 
Although these small retrospective reviews cannot be used to extrapolate general treatment for 
patients with metastatic melanoma, there may be a survival advantage for the surgical resection 
of isolated splenic metastases. 
 
Breast Cancer 
Isolated splenic metastasis from breast cancer is exceeding rare. In a review of 92 patients with 
secondary splenic metastases, Lam and Tang found four patients with primary breast cancer.91 
Among the population with breast cancer, there have been few case reports of isolated splenic 
metastasis.91,104-107 Of the five reported cases, two patients presented with idiopathic 
thrombocytopenic purpura, one with a splenic mass by routine ultrasound, and two with 
abdominal pain and splenomegaly. The patients all had a splenectomy with favorable short-term 
outcomes. 
Gastric Cancer 
While direct splenic invasion from gastric carcinoma may occur, discontiguous splenic 
metastases from gastric cancer are uncommon. Lam and Tang report 16% of metastatic tumors to 
the spleen to be secondary to gastric cancer.91 Agha-Mohammadi et al found only one case of 
gastric cancer with a solitary metastasis to the spleen in their extensive literature review.78 
Yamanouchi et al reviewed all reported cases of isolated metachronous and synchronous 
splenic metastases from gastric cancer, identifying a total of 11 patients.  This review 
demonstrated that in the majority of cases, the primary tumors are located in the upper to middle 
third of the stomach. Gastric cancer is thought to metastasize to the spleen via the splenic artery, 
because there have been few reports of nodal metastases at the hilum or of tumor embolism in 
the splenic vein. It is important to remember that the blood flow from the stomach does not reach 
the spleen directly but rather through the systemic circulation. Therefore, in most cases there are 
likely to be undetectable micrometastases in other organs.108 As with other primary cancers, 
gastric cancer that metastasizes to the spleen is treated with splenectomy.  
 
Renal Cell Carcinoma 
Splenic metastases from a renal cell primary are rare, but they do represent 1.8% of all splenic 
metastases in autopsy data.91 Usually splenic involvement is via direct invasion from the left 
kidney.109 To the best of our knowledge, there have been no more than a few isolated 
case reports of RCC metastasizing to the spleen.109-111 These patients were treated successfully 
with splenectomy, and the patients were disease free at follow-up. 
 
CONCLUSION 
Isolated metastases to pancreas and spleen occur rarely. Most often these metastases are 
associated with disseminated disease. The most common primaries with isolated pancreatic 
metastases include renal cell carcinoma, lung cancer, and breast cancer. On the other hand, the 
most common primaries associated with splenic metastases are gynecologic—primarily 
ovarian. Review of the literature shows that in appropriate patients with isolated metastases and 
prolonged disease-free interval, long-term survival can be achieved with resection of these 
metastases. 
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